›› 2012, Vol. 32 ›› Issue (2): 226-.doi: 10.3969/j.issn.1674-8115.2012.02.022

• Review • Previous Articles     Next Articles

Update on anti-vascular endothelial growth factor treatment for diabetic macular edema

SUO Yan, LIU Kun, XU Xun   

  1. Department of Ophthalmology, the First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China
  • Online:2012-02-28 Published:2012-02-28
  • Supported by:

    Shanghai Key Laboratory for Ocular Fundus Diseases Foundation, 07Z22911

Abstract:

Diabetic macular edema (DME) is one of the major causes of visual impairment in patients with diabetes mellitus. The major treatment methods for DME include laser photocoagulation therapy, anti-inflammatory therapy and anti-vascular endothelial growth factor (VEGF) therapy. In recent years, anti-VEGF drugs such as Ranibizumab, Bevacizumab, VEGF-Trap and KH902 have exhibited favorable effects in treatment of DME. The research progress of anti-VEGF therapy for DME is reviewed in this paper, and the efficacy and safety of anti-VEGF therapy are explored.

Key words: diabetic macular edema, laser photocoagulation, anti-inflammatory therapy, anti-vascular endothelial growth factor drug